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Background/aim: Sonographic assessment of diaphragm structure and function would be a useful clinical tool in patients with chronic
obstructive pulmonary disease (COPD). Our aim was to determine the muscle thickness of the diaphragm and the usefulness of clinical
practice in patients with COPD.
Materials and methods: The diaphragmatic thickness of 34 COPD patients and 34 healthy subjects was measured during tidal volume
(Tmin) and deep inspiration (Tmax) on both sides using a B-mode ultrasound. The body mass index and the modified Medical Research
Council (mMRC) index values were reported.
Results: There was no correlation among TminR (P = 0.134), TminL (P = 0.647), TmaxR (P = 0.721), and TmaxL (P = 0.905) between
the patients with COPD and the control group. There was also no significant difference between diaphragmatic thickness and COPD
severity, respiratory function (P = 0.410), and frequency of exacerbations (P = 0.881) and mMRC (P = 0.667).
Conclusion: Diaphragmatic dysfunction in COPD is related to mobility restriction rather than muscle thickness.
Key words: Chronic obstructive pulmonary disease, diaphragm, chest ultrasound

1. Introduction
Chronic obstructive pulmonary disease (COPD) is
characterized by a progressive restriction of airways.
Structural damage in the lung parenchyma causes
pulmonary hyperinflation. This condition restricts
diaphragmatic mobility in patients with severe COPD. The
diaphragm flattens, reducing the upward and downward
movement of the lung. In patients with severe COPD, the
contraction of the auxiliary respiratory muscles, such as
the sternocleidomastoid and scalene muscles, compensates
for the insufficiency of diaphragm, the main respiratory
muscle [1].
Loss of fat-free mass (FFM) and weakened skeletal
muscles caused by factors including reduced protein
production, malnutrition, increased muscular apoptosis,
oxidative stress, inflammatory mediators in systemic
circulation, and steroid use also play a role in diaphragmatic
dysfunction in COPD patients in addition to pulmonary

hyperinflation [2–4]. In COPD, loss of muscle mass has
been described as the key determinant of mortality,
independent of lung function, smoking, and body mass
index (BMI) [5].
In severe COPD patients with FFM and muscle loss,
the mass and thickness of the diaphragm may vary greatly.
Autopsy examinations in these patients have shown
reduced diaphragmatic thickness, volume, and surface
compared to those without COPD [6]. Accordingly,
evaluation of diaphragmatic function is getting more
important in COPD patients. In these patients fluoroscopy
is not a reliable approach for measuring diaphragmatic
thickness; computerized tomography involves radiation
exposure, and magnetic resonance imaging may yield
better results, but it is more expensive. Therefore,
ultrasonography appears to be a good option for
measuring diaphragmatic dysfunction [4,7]. Although
ultrasonographic measurement of diaphragmatic
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thickness is a simple, accurate, affordable, and repeatable
method, sufficient information is not available at this time
to establish whether it represents a significant indicator of
severity of disease, symptoms, quality of life, and mortality.
To our knowledge, there are few reports available
concerning the relationship between diaphragm mobility
and COPD severity. There are also several methods for
measuring the function of the diaphragm, and which
sonographic method is most effective has not yet been
defined. For this reason, contradictory results have been
reported in the literature.
In this study, the diaphragmatic thicknesses of patients
with moderate and severe COPD were measured using
ultrasonography and compared with healthy controls in
order to evaluate the relationship between the thickness of
the diaphragm and the severity of parameters and clinical
characteristics of the disease.
2. Materials and methods
2.1. Study design and setting
This observational case-control study was carried out at a
large tertiary referral academic institution after receiving
institutional review board approval (No. 20171207-2).
All patients gave verbal and written consent. The study
included stable COPD patients admitted from December
2017 to February 2018. The diagnosis of COPD was based
on an investigation of their medical history, a clinical
examination, and respiratory function tests. COPD
diagnoses of the patients were made based on the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria. The patients were asked about smoking, exposure
history, annual number of exacerbations, presence of
concomitant conditions, and duration of the disease. The
symptom scores were captured using the modified Medical
Research Council Dyspnea Scale (mMRC). Patients
older than 40 years who had a postbronchodilator forced
expiratory volume in the first second/forced vital capacity
(FEV1/FVC) ratio of <70% on pulmonary function testing
(PFT) (Vmax Encore PFT System, USA), measured by
the same trained operator according to ATS standards,
were enrolled in the study. Serum glucose, urea, creatine,
albumin, lipid profile, electrolytes, hemogram, B12, and
folic acid levels were recorded. Echocardiographic (ECO)
evaluation, ejection fractions (EF), and pulmonary artery
pressure (PAP) levels were noted. Thirty-four patients with
COPD and 34 healthy subjects who had been admitted to
a university hospital were enrolled. Patients with acute
exacerbation of COPD, malignancy, neuromuscular
conditions, cerebrovascular disease, unilateral or bilateral
pleural effusion, pneumothorax, atelectasis, pneumonia,
interstitial lung disease, or a recent surgical operation and
those who did not consent to participating in the study were
excluded. Comorbidities, including cardiac insufficiency,
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hypertension, renal insufficiency, and diabetes mellitus,
were asked about and recorded.
2.2. Measurements
All sonography exams were performed when patients were
in a supine position before and after deep inspiration. Both
arms were positioned higher than the neck. The junction
of diaphragmatic branches to the interior side of lateral
chest walls were identified through the intercostal space
by an axial view. The probe was rotated 90 degrees to
see the diaphragmatic branches as parallel to the probe
beams. The thickness of the right and left branches was
measured before patients took a deep breath. Measured
diaphragm thicknesses were recorded as TminR (right)
and TminL (left). Patients were requested to take a deep
breath and hold it for 10 to 20 s during the evaluation for
both sides. The thicknesses of the branches were measured
after holding the inflated chest still. The measurements
were recorded as TmaxR (right) and TmaxL (left). A
high-resolution linear probe (Voluson, General Electric
Imaging, USA) with gray-scale imaging was used by one
experienced radiologist. Three consecutive measurements
were taken before and after deep inspiration and the
average value of that series was calculated and recorded as
a final result for both sides. All evaluations were made by
the same radiologist who was blinded to the pulmonary
function status of each patient.
The patients were divided into 4 groups, as Group
A, Group B, Group C, and Group D, based on symptom
score and number of exacerbations. Based on spirometry,
patients with a FEV1 value of >80% were classified as
having mild COPD, between 80% and 50% as having
moderate COPD, between 49% and 30% as having severe
COPD, and <29% as having very severe COPD.
2.3 Statistical analysis
SPSS 21 (IBM Corp., Armonk, NY, USA) was used for
statistical analysis. Data are presented as mean ± SD or
n (%), as appropriate. Correlations between continuous
variables were tested using Spearman’s rho. Normality
was tested using the Shapiro–Wilk Test. Student’s t-test
was used for parametric variables and the Mann–
Whitney U test was used for nonparametric variables
for the differences between 2 groups in terms of Tmin–
Tmax (diaphragm thickness). P < 0.05 was considered an
indication of statistical significance.
3. Results
The 34 COPD patients, 29 males and 5 females, who
were enrolled in the study had an average age of 71 ± 9
years and an average disease duration of 7.1 ± 5.4 years.
There were 9 patients in GOLD Group C and 25 in
Group D. Fourteen cases were categorized as moderate,
15 as severe, and 5 as very severe based on respiratory
function. There were 8 patients with minor symptoms
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and 26 with advanced symptoms based on the symptom
scores (mMRC). According to number of exacerbations,
27 patients had 2 or fewer, and 7 patients had more than
2. Patient demographics and clinical characteristics are
shown in Table 1.
Diaphragmatic thickness was measured separately
on the left and the right side, both during tidal volume
(Tmin) and deep inspiration (Tmax), and the measured
results were correlated. There was no significant difference
between the patient and control groups in diaphragmatic
thickness. The results are shown in Table 2.
There was no correlation between diaphragmatic
thickness and COPD severity, respiratory function,
frequency of exacerbations, smoking, or demographics.
The results are shown in Table 3.
When the patients were divided into 2 groups based on
the number of annual exacerbations, respiratory severity,
GOLD stage, symptom severity, and disease duration,
we could not find a significant difference in terms of
diaphragmatic thickness between the groups. The results
are shown in Table 4.
There was no signification correlation between the
patients’ serum albumin, urea, creatine, magnesium,
calcium, B12, folic acid, cholesterol, and triglyceride levels
and diaphragmatic thickness.
4. Discussion
Contrary to our expectations, there was no significant
difference in terms of diaphragmatic thickness between

the control group and the group of patients with moderate
and severe COPD. Additionally, ultrasonographic
measurement of diaphragmatic thickness, although an
affordable, quick, and repeatable method, was insufficient
in identifying those with high symptom scores and high
risk of exacerbation. There was no relationship between
diaphragmatic thickness and disease severity, disease
duration, FEV1, symptom score, and frequency of
exacerbations. Moreover, there was no correlation with
concomitant conditions, blood gas values, and serum
biochemistry parameters.
Although it has been known for approximately 4 decades
that the diaphragm is affected in COPD, the number of
studies measuring diaphragmatic function is relatively
low due to reasons such as the absence of standardization
of the measurement methods [6,7]. Although patients’
diaphragmatic function is affected, studies have reported
conflicting results, due to the complex functionality of the
diaphragmatic muscle and nonstandardized measurement
methods. For example, Baria et al. measured diaphragmatic
thickness by ultrasonography in 50 COPD patients
and 150 healthy controls and reported the absence of a
significant difference in diaphragmatic thickness between
the COPD patients and the controls. This study did not
investigate the relationship of diaphragmatic thickness
with clinical characteristics [8]. Eryüksel et al. did not
identify a significant difference between diaphragmatic
thickness fraction and disease severity, symptom severity,
frequency of episodes, FEV1 value, and BMI [9]. Similarly,

Table 1. Demographic and clinical characteristics of patient and control groups.
COPD group (n: 34)

Control group (n: 34)

P

Sex, M/F

29/5

20/14

0.001

Age (mean ± SD), years

71.0 ± 9.2

65 ± 7.1

0.012

Body mass index (mean ± SD), kg/m2

25.8 ± 4.9

27.5 ± 3.7

0.08

Smoking pack-years (mean ± SD)

39.2 ± 21

17.6 ± 17.6

0.001

Smoking (none/current/former)

4/1/29

14/9/11

Number of exacerbations within the last year, mean ± SD [min/max]

1.94 ± 1.3 [1/6]

FEV1/FVC, mean ± SD [min/max]

53 ± 10.2 [29/70]

FEV1, mean ± SD [min/max] (% pred.)

45.1 ± 14.6 [20/73]

mMRC score, mean ± SD

2 ± 0.7

GOLD class A/B/C/D

-/-/9/25

Spirometric class (moderate/severe/very severe), n

14/15/5

pCO2, mean ± SD [min/max]

40.6 ± 11 [25.7/87.2]

pO2, mean ± SD [min/max]

56.7 ± 9.3 [33.5/78.2]

Saturation O2, mean ± SD [min/max]

89.8 ± 4.7 [78/96]

FEV1: Forced expiratory volume in the first second; mMRC: modified Medical Research Council Dyspnea Scale; GOLD: Global
Initiative for Chronic Obstructive Lung Disease.
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Table 2. Comparison of groups in terms of diaphragm thickness.
Thickness mm

COPD group (n: 34)

Control group (n: 34)

P

TminR

2.74 ± 0.4

2.98 ± 0.8

0.134

TminL

2.77 ± 0.4

2.70 ± 0.7

0.647

TmaxR

4.40 ± 0.8

4.47 ± 0.8

0.721

TmaxL

4.41 ± 0.7

4.44 ± 0.7

0.905

TminR: Minimum thickness right; TminL: minimum thickness left; TmaxR: maximum
thickness right; TmaxR: maximum thickness left.
Table 3. Correlations of diaphragm thickness with demographic and clinical data.
TminR

TmaxR

Characteristics

r

P

r

P

GOLD group

–0.09

0.6

0.06

0.7

Spirometric function

–0.33

0.06

–0.03

0.8

Frequency of exacerbations

–0.18

0.3

–0.04

0.8

Duration of COPD

–0.22

0.2

–0.16

0.3

FEV1

0.19

0.3

–0.18

0.3

mMRC score

–0.13

0.5

–0.01

0.9

pCO2

–0.02

0.9

0.05

0.8

pO2

–0.12

0.5

–0.01

0.9

Saturation O2

–0.14

0.4

–0.05

0.8

Age

–0.14

0.4

–0.28

0.1

Smoking status

0.26

0.1

0.24

0.2

BMI

0.08

0.7

0.24

0.2

EF

–0.08

0.7

0.10

0.6

PAP

–0.123

0.5

0.01

0.9

FEV1: Forced expiratory volume in the first second; mMRC: modified Medical
Research Council; GOLD: Global Initiative for Chronic Obstructive Lung Disease;
BMI: body mass index; EF: ejection fraction; PAP: pulmonary artery pressure.

a study by Cimsit et al. could not establish a correlation
between clinical parameters and diaphragmatic thickness
[10]. However, the last 2 studies did not include a control
group. In contrast, Smargiassi et al. reported that their
thickness measurements by echocardiography were related
to hyperinflation and lung volume. Additionally, the FFM,
BMI, and BODE (BMI-Obstruction-Dyspnea-Exercise)
index were correlated with diaphragmatic thickness.
However, only 23 patients were evaluated [4].
Even though there were contradictory results with
diaphragmatic thickness, studies involving measurement
of the diaphragm on the craniocaudal plane during
inspiration and expiration (excursion/lung silhouette)
have reported more consistent results. Scheibe et
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al. reported that ultrasonographic measurement of
lung silhouette movement was useful and reliable in
demonstrating diaphragmatic dysfunction in patients with
COPD. This study showed a strong correlation between
diaphragmatic movement and FEV1 [3]. In a study
comparing 25 COPD patients with 25 healthy controls,
Davachi et al. detected statistically significant differences
between the 2 groups in terms of diaphragmatic mobility.
Also, in this study, diaphragmatic mobility was linked with
airway obstruction [11]. Similarly, Paulin et al. observed
reduced diaphragmatic mobility in patients with COPD
compared to healthy controls. In this study, diaphragmatic
mobility was related to hyperinflation. Those with lower
diaphragmatic mobility were more dyspneic and had
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Table 4. The relationship between diaphragm thickness and COPD severity.
n

Tmin R

<2

17

2.83 ± 0.5

≥2

17

2.64 ± 0.4

C

9

2.80 ± 0.6

D

25

2.72 ± 0.3

<2

8

2.91 ± 0.6

≥2

26

2.66 ± 0.4

<50%

20

2.66 ± 0.4

≥50%

14

2.86 ± 0.5

<10 years

22

2.79 ± 0.4

≥10 years

12

2.65 ± 0.4

≤2

28

2.72 ± 0.4

>2

6

2.80 ± 0.5

P

Tmax R

P

Frequency of exacerbations
0.188

4.60 ± 0.9
4.21 ± 0.7

0.171

GOLD group
0.779

4.32 ± 0.9
4.44 ± 0.8

0.667

mMRC
0.328

4.49 ± 0.8
4.38 ± 0.8

0.839

FEV1
0.290

4.48 ± 0.8
4.30 ± 0.8

0.410

Duration of COPD
0.337

4.52 ± 0.8
4.20 ± 0.9

0.295

Comorbidities
0.702

4.38 ± 0.8
4.55 ± 0.7

0.642

FEV1: Forced expiratory volume in first second; mMRC: modified Medical Research Council;
GOLD: Global Initiative for Chronic Obstructive Lung Disease.

shorter 6-min walk distances [12]. In a study by Ünal
et al., the travel difference between the diaphragmatic
points was 26 mm for patients with COPD and 69 mm
for healthy subjects using MR fluoroscopy. Also, excursion
was correlated with FEV1 [13]. In a study of 37 COPD
patients, Kang et al. reported a positive correlation for
diaphragmatic mobility with FEV1 and FVC, and negative
correlation with RV, TLC, and PaCO2 [14]. In a similar
study, there was a reduction of the diaphragm movement
distance compared to healthy subjects, and a correlation
was described between diaphragm movement and airway
obstruction (FEV1) [15].
Based on our findings and those of similar studies, we
have reached the conclusion that diaphragmatic dysfunction
in COPD is related to mobility restriction, rather than
muscle thickness, which was the basis of our study
hypothesis. Pulmonary hyperinflation affects excursion
more prominently than thickness. Perhaps, contrary to
our original proposition, diaphragmatic thickness is not
adversely affected in COPD, due to overworking against
an increased mechanical load. Chronic load may lead
to adaptation, as with the skeletal muscle. Nevertheless,
further investigation of the respiratory muscle function
over time appears to be warranted.

Our study had a number of limitations. First, we were
unable to measure lung volumes. Data such as residual
volume (RV) or total lung capacity (TLC) to prove
hyperinflation were not available to the investigators.
However, all of our patients were in Groups C and D,
moderate and severe COPD patients, and most of them had
clinical/radiological evidence of hyperinflation. Second,
we were unable to perform bioelectrical impedance
analysis to prove loss of muscle mass. In particular,
evaluation of patients with notable cachexia and low FFM
in the different groups could provide useful data, whereas
we were able to use only BMI data and failed to identify a
significant difference.
There has been growing interest in chest ultrasonography
in recent years. Its area of use is expanding, particularly
in diagnosis and follow-up of respiratory conditions
including pneumothorax, acute and chronic interstitial
diseases, pneumonia, and pleural effusion. Even though
we have no significant results, our study has shown that the
establishment of a proven area of use in COPD may benefit
clinical practice. Further investigations are necessary for
standardizing the technique and supporting selection of
appropriate parameters for determining disease severity,
risk of exacerbation, and mortality prediction.

1077

OGAN et al. / Turk J Med Sci
References
1.

Martinez FJ, Couser JI, Celli BR. Factors influencing
ventilatory muscle recruitment in patients with chronic airflow
obstruction. American Review of Respiratory Disease 1990;
142 (2): 276-282. doi: 10.1164/ajrccm/142.2.276

9.

Eryüksel E, Cimsit C, Bekir M, Cimsit Ç, Karakurt S.
Diaphragmatic thickness fraction in subjects at high-risk for
COPD exacerbations. Respiratory Care 2017; 62 (12): 15651570. doi: 10.4187/respcare.05646

2.

Ottenheijm CA, Heunks LM, Sieck GC, Zhan WZ, Jansen
SM, et al. Diaphragm dysfunction in chronic obstructive
pulmonary disease. American Journal of Respiratory and
Critical Care Medicine 2005; 172 (2): 200-205. doi: 10.1164/
rccm.200502-262OC

10.

Cimsit C, Bekir M, Karakurt S, Eryüksel E. Ultrasound
assessment of diaphragm thickness in COPD. Marmara Medical
Journal 2016; 29 (1): 8-13. doi: 10.5472/MMJoa.2901.02

11.

Davachi B, Lari SM, Attaran D, Tohidi M, Ghofraniha L et
al. The relationship between diaphragmatic movements in
sonographic assessment and disease severity in patients with
stable chronic obstructive pulmonary disease (COPD). Journal
of Cardio-Thoracic Medicine 2014; 2 (3): 187-192.

12.

Paulin E, Yamaguti WP, Chammas MC, Shibao S, Stelmach R
et al. Influence of diaphragmatic mobility on exercise tolerance
and dyspnea in patients with COPD. Respiratory Medicine
2007; 101 (10): 2113-2118. doi: 10.1016/j.rmed.2007.05.024

13.

Unal O, Arslan H, Uzun K, Ozbay B, Sakarya ME. Evaluation
of diaphragmatic movement with MR fluoroscopy in chronic
obstructive pulmonary disease. Clinical Imaging 2002; 24 (6):
347-350. doi: 10.1016/S0899-7071(00)00245-X

14.

Kang HW, Kim TO, Lee BR, Yu JY, Chi SY et al. Influence
of diaphragmatic mobility on hypercapnia in patients with
chronic obstructive pulmonary disease. Journal of Korean
Medical Science 2011; 26 (9): 1209-1213. doi: 10.3346/
jkms.2011.26.9.1209

15.

Dos Santos Yamaguti WP, Paulin E, Shibao S, Chammas
MC, Salge JM et al. Air trapping: the major factor limiting
diaphragm mobility in chronic obstructive pulmonary disease
patients. Respirology 2008; 13 (1): 138-144. doi: 10.1111/j.14401843.2007.01194.x

3.

4.

Scheibe N, Sosnowski N, Pinkhasik A, Vonderbank S, Bastian
A. Sonographic evaluation of diaphragmatic dysfunction in
COPD patients. International Journal of Chronic Obstructive
Pulmonary Disease 2015; 10 (1): 1925-1930. doi: 10.2147/
COPD.S85659
Smargiassi A, Inchingolo R, Tagliaboschi L, Di Marco
Berardino A, Valente S et al. Ultrasonographic assessment
of the diaphragm in chronic obstructive pulmonary disease
patients: relationships with pulmonary function and the
influence of body composition - a pilot study. Respiration
2014; 87 (5): 364-371. doi: 10.1159/000358564

5.

Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J et al.
Midthigh muscle cross-sectional area is a better predictor
of mortality than body mass index in patients with chronic
obstructive Pulmonary disease. American Journal of
Respiratory and Critical Care Medicine 2002; 166 (6): 809-813.
doi: 10.1164/rccm.2107031

6.

Steele RH, Heard BE. Size of the diaphragm in chronic
bronchitis. Thorax 1973; 28 (1): 55-60. doi: 10.1136/thx.28.1.55

7.

Sferrazza Papa GF, Pellegrino GM, Di Marco F, Imeri G,
Brochard L et al. A review of the ultrasound assessment of
diaphragmatic function in clinical practice. Respiration 2016;
91 (5): 403-411. doi: 10.1159/000446518

8.

Baria MR, Shahgholi L, Sorenson EJ, Harper CJ, Lim K et al.
B-mode ultrasound assessment of diaphragm structure and
function in patients with COPD. Chest 2014; 146 (3): 680-685.
doi: 10.1378/chest.13-2306

1078

